American Diabetes Association
2 files

Nrf2 Regulates β-cell Mass by Suppressing β-Cell Death and Promoting β-Cell Proliferation

posted on 2022-04-27, 17:55 authored by Sharon Baumel-Alterzon, Liora S. Katz, Gabriel Brill, Clairete Jean-Pierre, Yansui Li, Isabelle Tse, Shyam Biswal, Adolfo Garcia-Ocaña, Donald K. Scott
Finding therapies that can protect and expand functional b-cell mass is a major goal of diabetes research. Here we generated b-cell-specific conditional knockout and gain-of-function mouse models and used human islet transplant experiments to examine how manipulating Nrf2 levels affects b-cell survival, proliferation and mass. Depletion of Nrf2 in b-cells results in decreased glucose-stimulated β-cell proliferation ex vivo and decreased adaptive β-cell proliferation and β-cell mass expansion after a high fat diet in vivo. Nrf2 protects b-cells from apoptosis after a high fat diet. Nrf2 loss-of-function decreases Pdx1 abundance and insulin content. Activating Nrf2 in a β-cell-specific manner increases β-cell proliferation and mass and improves glucose tolerance. Human islets transplanted under the kidney capsule of immunocompromised mice and treated systemically with CDDO-Me, an Nrf2 activator, display increased β-cell proliferation. Thus, by managing ROS levels, Nrf2 regulates β-cell mass and is an exciting therapeutic target for expanding and protecting b-cell mass in diabetes.


NIH/NIDDK, DK114338 (DKS); DK020541, DK105015, and DK126450, AG-O and a Mindich Child Health and Development Institute Pilot and Feasibility Grant; Mindich Post-doc Pilot Award (SA-B)